IP Library Granted Patent US 10,513,503
Granted Patent B2
US 10,513,503 · App. 15/577,173 · Granted Dec 24, 2019

Use of 3-deoxyanthocyanidins for treating occular diseases

Inventors: Valerie Fontaine (Cachan, FR); Rene Lafont (Paris, FR); Jose-Alain Sahel (Paris, FR); Stanislas Veillet (Savigny-sur-Orge, FR)
Assignees: BIOPHYTIS; SORBONNE UNIVERSITE; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
C07D311/60A61K31/352
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,503
App. No.
15/577,173
Granted
Dec 24, 2019
Kind
B2
Abstract

Disclosed is a method for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, including the application of a 3-deoxyanthocyanidin of formula (I) in which R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X − are as defined, with the condition that at least one of R 1 , R 2 , R 3 , R 4 or R 5 is a hydroxyl and at least one of R 8 , R 9 , R 10 or R 11 is a hydroxyl.

Claims (24)

1. A method for treating and/or stabilising AMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, comprising the administration to a patient in need thereof of an effective amount of a compound of Formula I

wherein

R 1 , R 2 , R 3 , R 4 and R 5 each independently is a group selected from hydrogen, halo, hydroxyl, alkoxy, aryloxy, heteroaryloxy, acyloxy, alkyl, aryl, aralkyl, alkylaryl, alkenyl, nitro, nitrile, amino, with the condition that at least one of R 1 , R 2 , R 3 , R 4 or R 5 is a hydroxyl;

R 6 is hydrogen;

R 7 is a group selected from hydrogen, halo, hydroxyl, alkoxy, aryloxy, heteroaryloxy, acyloxy, alkyl, aryl, aralkyl, alkylaryl, alkenyl, nitro, nitrile, amino;

R 8 , R 9 , R 10 and R 11 each independently is a group selected from hydrogen, halo, hydroxyl, alkoxy, aryloxy, heteroaryloxy, acyloxy, alkyl, aryl, aralkyl, alkylaryl, alkenyl, nitro, nitrile, amino, with the condition that at least one of R 8 , R 9 , R 10 or R 11 is a hydroxyl; and

X − is an anion selected from: anion derived from a mineral acid; anion derived from an organic acid; or an anion derived from a sulphate or sulphonate group.

2. The method according to claim 1 , wherein the anion derived from a mineral acid is selected from a bromide, chloride, borotetrafluoride and perchloride anion; and wherein the anion derived from an organic acid is selected from an acetate, borate, citrate, tartrate, bisulphate, sulphate and phosphate anion.

3. The method according to claim 1 , wherein the compound is of Formula Ia

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 10 and X − are such as defined in claim 1 .

4. The method according to claim 1 , wherein:

R 1 , R 2 , R 3 , R 4 and R 5 each independently is a group selected from hydrogen, hydroxyl and alkoxy, with the condition that at least one of R 1 , R 2 , R 3 , R 4 or R 5 is a hydroxyl; and

R 8 and R 10 each independently is a group selected from hydrogen, hydroxyl and alkoxy, with the condition that at least one of R 8 or R 10 is a hydroxyl.

5. The method according to claim 1 , wherein the compound is of Formula Ib

wherein R 1 , R 2 , R 3 , R 8 and X − are such as defined in claim 1 .

6. The method according to claim 1 , wherein R 8 is a hydrogen atom.

7. The method according to claim 1 , wherein the compound is selected from:

2′,7-dihydroxy-4′-methoxy-flavylium chloride;

2′,3′,7-trihydroxy-4′-methoxy-flavylium chloride;

3′,7-dihydroxy-4′-methoxy-flavylium chloride;

4′,5,7-trihydroxy-flavylium chloride;

3′,5,7-trihydroxy-4′-methoxy-flavylium chloride;

3′,4′,5′,5,7-pentadroxy-flavylium chloride; and

3′,4′,5,7-tetrahydroxy-flavylium chloride.

Assignments (2)
MERGER Recorded Oct 30, 2019
From: UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC)
To: SORBONNE UNIVERSITE
Reel/Frame 050862/0825 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2018
From: FONTAINE, VALERIE; LAFONT, RENE; SAHEL, JOSE-ALAIN; VEILLET, STANISLAS
To: BIOPHYTIS; UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Reel/Frame 045095/0706 →
Priority Claims (1)
FR 15 54761 · May 27, 2015 · national
Continuity (1)
Related Publication 20180230119A1 · Aug 16, 2018